NCT04660045View on ClinicalTrials.gov

Early Intervention With Acalabrutinib in Patients With High Risk CLL

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
Chronic Lymphocytic LeukemiaCLL/SLL
Interventions
DRUG

Acalabrutinib

Acalabrutinib, oral, 100 mg BID, continuous

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER